We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.59%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$998M
AUM Growth
+$20.9M
Cap. Flow
-$63M
Cap. Flow %
-6.31%
Top 10 Hldgs %
28.11%
Holding
91
New
2
Increased
24
Reduced
43
Closed
3

Top Buys

Rank Stock Value
1
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$22M
2
CI icon
Cigna
CI
+$8.21M
3
AERI
Aerie Pharmaceuticals
AERI
+$7.07M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$6.46M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$6.29M

Top Sells

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$22.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$17.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
4
WBA
Walgreens Boots Alliance
WBA
+$12.6M
5
LOXO
Loxo Oncology, Inc
LOXO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Financials 1.12%
3 Technology 0.14%
4 Energy 0.14%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
26
Edwards Lifesciences
EW
$51.7B
$16.8M 1.68%
289,755
+84,663
+41% +$4.14M
CELG
27
DELISTED
Celgene Corp
CELG
$16.2M 1.62%
180,698
-30,000
-14% -$2.65M
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$15.7M 1.57%
353,961
-52,400
-13% -$2.41M
KYNB
29
Kyntra Bio
KYNB
$29.4M
$15.3M 1.53%
10,048
+466
+5% +$718K
ALNY icon
30
Alnylam Pharmaceuticals
ALNY
$29.3B
$15M 1.51%
171,950
+57,983
+51% +$5.83M
GILD icon
31
Gilead Sciences
GILD
$165B
$14.6M 1.47%
189,647
-72,380
-28% -$5.47M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$2.87B
$14.5M 1.45%
1,290,495
+443,019
+52% +$6.29M
ITCI
33
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.2M 1.42%
654,982
-41,975
-6% -$878K
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
$13.9M 1.39%
180,000
-50,000
-22% -$3.68M
AGN
35
DELISTED
Allergan plc
AGN
$13.3M 1.34%
70,045
-55,000
-44% -$10.1M
BSX icon
36
Boston Scientific
BSX
$71.5B
$13M 1.3%
337,968
-10,000
-3% -$349K
ALKS icon
37
Alkermes
ALKS
$8.25B
$12.8M 1.28%
301,610
+11,610
+4% +$504K
ABBV icon
38
AbbVie
ABBV
$435B
$12.3M 1.23%
130,000
+60,000
+86% +$5.69M
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$12.3M 1.23%
188,272
-10,000
-5% -$588K
LIVN icon
40
LivaNova
LIVN
$4.2B
$11.8M 1.18%
95,000
+10,000
+12% +$1.18M
ARRY
41
DELISTED
Array Biopharma Inc
ARRY
$11.7M 1.17%
768,370
+45,000
+6% +$690K
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.93B
$11.2M 1.12%
145,428
-15,000
-9% -$1.21M
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$11.1M 1.11%
180,000
+110,000
+157% +$7.07M
BIIB icon
44
Biogen
BIIB
$30.7B
$10.6M 1.06%
30,000
+17,000
+131% +$5.85M
WBA
45
DELISTED
Walgreens Boots Alliance
WBA
$10.6M 1.06%
145,000
-185,000
-56% -$12.6M
AET
46
DELISTED
Aetna Inc
AET
$10.1M 1.02%
50,000
-20,000
-29% -$3.91M
NBIX icon
47
Neurocrine Biosciences
NBIX
$16.6B
$10M 1.01%
81,677
-28,700
-26% -$3.26M
FLXN
48
DELISTED
Flexion Therapeutics, Inc.
FLXN
$9.97M 1%
532,812
+181,026
+51% +$4.16M
COR icon
49
Cencora
COR
$61.2B
$9.36M 0.94%
101,520
-22,741
-18% -$1.97M
IMMU
50
DELISTED
Immunomedics Inc
IMMU
$8.86M 0.89%
425,330
-30,000
-7% -$711K
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rhenman & Partners Asset Management held 91 positions worth $998M, up 2.1% from $977M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $63M in Q3 2018, closing 3 positions and reducing 43 holdings. Its most notable exit was Express Scripts Holding Company, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Pediatrix Medical worth $5.82M.

  • Rhenman & Partners Asset Management's largest Q3 2018 buy was Pediatrix Medical: 124,674 shares worth $5.82M.
  • Rhenman & Partners Asset Management added most to DIPLOMAT PHARMACY, INC. in Q3 2018, an estimated $22M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2018 reduction was Nektar Therapeutics, cutting an estimated $17.8M.
  • Rhenman & Partners Asset Management fully exited Express Scripts Holding Company in Q3 2018, selling an estimated $22.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $998M portfolio in Q3 2018.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 3 in Q3 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 2.1% quarter-over-quarter to $998M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2018, filed 3 Oct 2018.